India to Germany: Pembrolizumab Export Trade Route

The India to Germany Pembrolizumab corridor is one of India's established pharmaceutical export routes, with 1 shipments documented worth a combined $124.8K USD. The route is dominated by GNH INDIA PHARMACEUTICALS LIMITED, which alone accounts for roughly 100% of all export value, reflecting the consolidated nature of India's pembrolizumab manufacturing sector.

Across 1 active suppliers, the average shipment value stands at $124.8K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 80% of all shipments, consistent with pembrolizumab's non-urgent bulk-order profile.

Shipment activity peaks during April–June, with an average transit time of 27 days port-to-port. The route has recorded an annual growth rate of 22.9%, placing it at rank #16 among India's top pembrolizumab export destinations globally.

On the import side, key buyers of Indian pembrolizumab in Germany include TO THE ORDER. TO THE ORDER is the single largest importer with 1 shipments valued at $124.8K USD.

India's pembrolizumab exports to Germany are driven primarily by a handful of large-scale manufacturers. GNH INDIA PHARMACEUTICALS LIMITED with 1 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 1 active exporters signals a competitive but concentrated market — buyers in Germany benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — GNH INDIA PHARMACEUTICALS LIMITED — together account for 100% of total trade value on this route. The average shipment value of $124.8K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.

On the buying side, TO THE ORDER is the largest importer with 1 shipments worth $124.8K USD — representing 100% of all pembrolizumab imports from India on this route.